Client news
Financings, listings, clinical milestones and partnerships announced by the biotech and medtech companies OG Advisors works with. Every entry links to the original announcement.
Updated October 2026
Browse news by client
BioStem Technologies news
Nasdaq: BSEM
Regenerative medicine company focused on wound care, with the VENDAJE® product line. Listed on Nasdaq under BSEM since August 2026.
-
Secures up to $40 million in a committed equity facility with Roth Principal Investments
-
Expands hospital access for VENDAJE® and VENDAJE AC® through the Vizient and Premier group purchasing organizations
-
To present at the H.C. Wainwright 28th Annual Global Investment Conference
-
To present at the Sidoti MicroCap Conference
-
Reports second quarter 2026 financial results
-
Announces Nasdaq uplisting, with trading expected to begin August 7, 2026 under “BSEM”
-
Publicly files its Form 10 registration statement with the SEC
-
To present at Planet MicroCap Las Vegas 2026
Hillhurst Bio news
Clinical-stage biopharmaceutical company developing HBI-002 for Parkinson’s disease.
-
Doses the first subject in its Phase 2a clinical trial of HBI-002 for Parkinson’s disease
-
Receives an FDA Study May Proceed letter to start a Phase 2a trial of HBI-002 in Parkinson’s disease
-
Receives a grant award from The Michael J. Fox Foundation and a grant subaward from the Farmer Family Foundation to advance clinical development in Parkinson’s disease
Deep Blue Medical Advances news
Medical device company developing products for surgical use.
-
Closes an oversubscribed $5.6 million Series A and promotes Lou Fuqua to Chief Operating Officer
OCMS Bio news
Antibody discovery company with a proprietary platform for high-throughput antibody selection based on function.
-
Selected to present at BioLabs Investor Day Philadelphia on April 21, 2026
LexBio news
AI-driven drug discovery company developing molecular glue degraders and therapies for hard-to-drug targets.
-
Interviewed by Geek Park on AI-driven drug discovery
-
CEO joins the “undruggable targets” panel at BIOCHINA 2026
-
Announces a strategic collaboration with Hiteck on AI-driven molecular glue degraders for immune diseases
-
CEO speaks at the 2025 CPHI China Pharmaceutical R&D Cloud Summit
-
Named an “Honored Enterprise” at the NVIDIA Inception Showcase 2025
Bound Therapeutics news
Early-stage therapeutics company, funded through its first pre-seed round.
-
Closes its first pre-seed financing round, bringing total funding to $3.4 million
What do your next 12 months look like?
Want your next milestone on this page?
Tell us about the partnership, financing, launch or deal in front of you. If we can help, we’ll tell you how. If we can’t, we’ll tell you that too.
